Biden Administration Set to Announce First Round of Drugs to Be Eligible for Medicare Negotiation by September 1
In the coming days, the Biden administration is set to announce the first round of drugs eligible for lower prices under the Medicare Drug Negotiation Program created by the Inflation Reduction Act. Ahead of the drug announcement, Protect Our Care is highlighting drugs that will likely be eligible for negotiation.
Today’s focus is Pfizer’s Ibrance, which is a treatment for breast cancer that could qualify for negotiation. Ibrance costs patients an average of $6,459 annually, an unthinkable sum for seniors with limited means or on fixed incomes. Meanwhile, with a list price of $181,663, Pfizer has been raking in billions of dollars on the sale of this drug alone. Read more about Ibrance and other drugs that could qualify for lower prices under the Inflation Reduction Act here.